POTT'S Disease
Downloads
Pott's disease, sometimes reffered to tuberculous spondylitis, is an infection of tuberculosis that affects one or more vertebrae, which first described by Percival Pott. Tuberculous spondylitis is the most dangerous form of musculoskeletal tuberculosis because it can cause bone destruction, deformity and paraplegia. The spine is the most commonly affected due to bony dissemination of tuberculosis in bones. The deployment through the arteries, veins via Batson plexus and percontinuitatum by the spread of abscess paravertebral. The spread of tuberculosis infection will cause inflammation in paradiscs, and causes progressive bone destruction and then will make vertebral collapse and deformity arising shaped kyphosis (posterior angulation) called gibbus. Early diagnosis is often difficult, MRI is the best diagnostic tools for pott's disease. Tissue culture or spesimen of M. tuberculosis important to confirm the diagnosis. Medical treatment is preferred, whereas surgical therapy as a complements. Drop out of anti-tuberculous drugs is a major challenge for the treatment of spinal TB with MDR because of long duration of therapy and the cost. The prognosis for spinal TB increases with early diagnosis and rapid intervention.
Global Tuberculosis Report 2014. World Health Organization, 2014.
Williams A, Hussell T, Lloyd C. Immunology: mucosal and body surface defences. Chichester, West Sussex; Hoboken, NJ: WileyBlackwell; 2012. xvii, p. 80.
Li W, Deng G, Li M, Liu X, Wang Y. Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection. Tuberculosis research and treatment. 2012; 2012: 791728.
Tjärnlund A. Does IgA play a role in protection against pulmonary tuberculosis? Sweden: Stockholm University; 2005.
Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clinical and experimental immunology. 2009; 157(2): 235–43.
Mayer AK, Dalpke AH. Regulation of local immunity by airway epithelial cells. Archivum immunologiae et therapiae experimentalis. 2007; 55(6): 353–62.
Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal immunology. 2008; 1(3): 183–97.
Lillehoj ER, Kim KC. Airway mucus: its components and function. Archives of pharmacal research. 2002; 25(6): 770–80.
Schutte BC, McCray PB, Jr. [beta]-defensins in lung host defense. Annual review of physiology. 2002; 64: 709–48.
Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis. 2004; 84(1–2): 93–101.
Li Y, Wang Y, Liu X. The role of airway epithelial cells in response to mycobacteria infection. Clinical & developmental immunology. 2012; 2012: 791392.
de Larrea CF, de Waard JH, Giampietro F, Araujo Z. The secretory immunoglobulin A response to Mycobacterium tuberculosis in a childhood population. Revista da Sociedade Brasileira de Medicina Tropical. 2006; 39(5): 456–61.
Sato S, Kiyono H. The mucosal immune system of the respiratory tract. Current opinion in virology. 2012; 2(3): 225–32.
Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal immunology. 2011; 4(3): 288–93.
Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology. 2010; 15(3): 433–50.
Kolls JK, Khader SA. The role of Th17 cytokines in primary mucosal immunity. Cytokine & growth factor reviews. 2010; 21(6): 443–8.
Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, et al. CD4(+)CD25(+) FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clinical immunology (Orlando, Fla). 2007; 123(1): 50–9.
Mihret A. The role of dendritic cells in Mycobacterium tuberculosis infection. Virulence. 2012; 3(7): 654–9.
Weiss G, Schaible UE. Macrophage defense mechanisms against intracellular bacteria. Immunological reviews. 2015; 264: 182–203.
Cavalcanti YV, Brelaz MC, Neves JK, Ferraz JC, Pereira VR. Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. Pulmonary medicine. 2012; 2012: 745483.
Cooper AM, Mayer-Barber KD, Sher A. Role of innate cytokines in mycobacterial infection. Mucosal immunology. 2011; 4(3): 252–60.
Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. Journal of immunology (Baltimore, Md: 1950). 2006; 177(9): 6353–60.
Reljic R, Sibley L, Huang JM, Pepponi I, Hoppe A, Hong HA, et al. Mucosal vaccination against tuberculosis using inert bioparticles. Infect Immun. 2013; 81(11): 4071–80.
Copyright (c) 2016 Tutik Kusmiati, Hapsari Paramita Narendrani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.